Product image of Infanrixtetra (Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin Adsorbed On A) supplied by GNH India

Infanrixtetra

Active Ingredient:
Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin Adsorbed On A
Origin:
EU

Infanrixtetra (Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin Adsorbed On A)

Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin, the active ingredient in Infanrixtetra, is a vaccine presented as an injectable formulation for intramuscular use. It induces immunity against poliovirus type 3 and pertussis, protecting children and adults from paralytic polio and whooping cough.
GNH India supplies Infanrixtetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratoire Glaxosmithkline

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Infanrixtetra is a combined inactivated poliovirus type 3 and pertussis filamentous haemagglutinin vaccine used to prevent viral and bacterial respiratory infections.

  • Poliomyelitis (type 3): provides active immunity that reduces the risk of paralytic disease caused by poliovirus type 3.
  • Pertussis (whooping cough): induces antibodies against pertussis filamentous haemagglutinin, helping prevent whooping cough.
  • Community protection: contributes to herd immunity against both poliomyelitis and pertussis, supporting public‑health immunisation programmes.

How It Works

  • Infanrixtetra contains inactivated poliovirus type 3 particles and purified pertussis filamentous haemagglutinin adsorbed onto an adjuvant. After intramuscular injection, antigen‑presenting cells process the proteins, stimulating B‑cell and T‑cell responses that generate neutralising antibodies and cellular immunity, thereby conferring protection against poliomyelitis type 3 and pertussis infection.

Side Effects

Vaccination may be accompanied by mild, transient reactions.

Common Side Effects

  • Injection site pain, redness or swelling.
  • Low‑grade fever.
  • Headache or mild fatigue.
  • Transient muscle aches.

Serious or Rare Side Effects

  • Anaphylactic or severe allergic reaction.
  • Seizures (rare).
  • Guillain‑Barré syndrome.
  • High fever persisting >48 hours.
  • Neurologic complications such as encephalitis.

Precautions & Warnings

Infanrixtetra should be administered with attention to specific safety considerations.

  • Allergy to vaccine components: avoid if severe hypersensitivity is known.
  • Immunocompromised individuals: assess risk‑benefit before use.
  • Acute febrile illness: defer vaccination until recovery.
  • Pregnancy: use only if potential benefits outweigh uncertain risks.
  • Breastfeeding: no specific contraindication, but monitor infant for reactions.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Vaccines can interact with other agents that modify immune response.

Major Interactions (Avoid)

  • Concurrent administration of blood products containing immunoglobulins: may diminish vaccine‑induced immunity.
  • Live viral vaccines given within 4 weeks: increased risk of interference with immune response.

Moderate Interactions (Monitor Closely)

  • Simultaneous receipt of other inactivated vaccines: generally safe but monitor for additive reactogenicity.
  • Immunosuppressive therapy (e.g., high‑dose steroids): may reduce antibody production.
  • Antipyretics taken prophylactically: may blunt expected mild fever response.

Frequently Asked Questions

Infanrixtetra is a combined vaccine that protects against poliomyelitis caused by poliovirus type 3 and against pertussis (whooping cough) by stimulating the immune system to produce specific antibodies.

The inactivated poliovirus type 3 particles and pertussis filamentous haemagglutinin are recognized by immune cells after intramuscular injection, prompting B‑cell and T‑cell activation that leads to the production of neutralising antibodies and cellular immunity against both pathogens.

The dose and schedule are determined by the prescribing clinician based on age, immunisation history and local public‑health guidelines. No fixed regimen is provided here.

Safety data are limited; the vaccine should only be given during pregnancy if the expected benefit outweighs potential risk. Breastfeeding is not a contraindication, but infants should be observed for any adverse reaction.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Infanrixtetra combines an inactivated poliovirus type 3 component with pertussis filamentous haemagglutinin, whereas some alternatives use whole‑cell or acellular pertussis antigens and may include additional poliovirus serotypes. The choice depends on regulatory approvals, immunogenicity profiles and local vaccination schedules.

The vaccine must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. It should be kept in the original packaging until use to maintain potency.

Infanrixtetra is given by a single intramuscular injection, typically into the deltoid or anterolateral thigh, according to the prescriber’s schedule and the patient’s age.

Serious adverse events, although rare, include anaphylaxis, Guillain‑Barré syndrome, seizures, and high‑grade fever lasting more than 48 hours. Immediate medical attention is required if any of these occur after vaccination.

Individuals with a known severe allergy to any vaccine component, those who have experienced a previous severe reaction to a similar vaccine, and persons with uncontrolled immunodeficiency should avoid this vaccine unless a risk‑benefit assessment justifies use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin Adsorbed On A

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT